Study lauds imaging method’s sensitivity in assessing MPM patients’ response to chemotherapy
Different imaging techniques can have different sensitivity in evaluating the response of malignant pleural mesothelioma (MPM) patients to chemotherapy, but a new study found a technique called 18F-FDG-PET/CT to be superior to others, and it called for the method’s inclusion in treatment assessments to help identify those not likely to respond to chemotherapy.
The study, “Metabolic Response Assessment With 18F-FDG-PET/CT Is Superior To Modified RECIST For The Evaluation Of Response To Platinum-Based Doublet Chemotherapy In Malignant Pleural Mesothelioma,” was published in the European Journal of Radiology. Read more.